RADIOIODINE THERAPY OF PAPILLARY THYROID CANCER, COMPLICATED BY A RADIAL MYELITIS. CLINICAL CASE

Over the past decades, there has been an increase in the incidence of thyroid cancer in most countries, and the most common form of thyroid cancer is papillary thyroid cancer. Application of radioiodine therapy for papillary thyroid cancer depends on the degree of postoperative risk of the disease recurrence. Radioactive iodine is recommended after radical thyroidectomy in case of intermediate or high risk of recurrence, that reduces the probability of disease progression and increases survival. The aim of radioiodine therapy is the ablation of thyroid tissue left after thyroidectomy and metastases, accumulating radioactive iodine. The recommended activity of the drug for radioablation is 30 mCi in the intermediate risk group and 30 to 150 mCi with a high risk of recurrence, but total doses and multiplicity of courses varies widely. The acute side effects of radioiodine therapy, the probability of which increases with a radioiodine dose of more than 100 mCi, include allergic reactions to iodine, post-radiation parotitis and sialadenitis, gastritis, cystitis, pulmonitis (with lung metastases), myelodepression, transient amenorrhea and hypo-spermia. The listed violations are transient and last from several days to several months. In the presented article the clinical case of papillary thyroid cancer with metastases in the lymph nodes of the neck was examined. The patient underwent thyroidectomy, central lymphadenectomy and radiotherapy. One year after the third course of radioiodine therapy the patient experienced the development of post-radiation gastritis, myelodepression and myelitis, manifested by a marked pain syndrome in the cervical spine and sensory and movement disorder of hands and legs. Pulse therapy with glucocorticoids in combination with drugs that improve microcirculation, neuromuscular conduction and reduce the severity of neuropathic disorders allowed to stop post-radiation complications.

1. Bel’cevich D.G., Vanushko V.Je., Mel’nichenko G.A. i dr. Project: Clinical recommendations of the Russian Endocrinology Association for the diagnosis and treatment of nodular goiter (new version of 2015). Jendokrinnaja hirurgija. 2015; 1: 15–21 [in Russian].

2. Bel’cevich D.G., Vanushko V.Je., Rumjancev P.O. i dr. Russian Clinical Recommendations for the Diagnosis and Treatment of Highly Differentiated Thyroid Cancer in Adults, 2017. Jendokrinnaja hirurgija. 2017; 11(1): 6–27 [in Russian].

3. Kijaev A.V. Comments on the section of the clinical recommendations of the American Thyroid Association on the diagnosis and treatment of nodular goiter in children. Klinicheskaja i jeksperimental’naja tireodologija. 2015; 11(4): 40–50 [in Russian].

4. Rebeko V.Ja., Rebeko I.V. Complications and long-term consequences of thyroid cancer radioiodine therapy. Medicinskie novosti. 2000; 6: 17–19 [in Russian].

5. Romanchishen A.F. Application of chromolymphography for the choice of volume of operations in patients with thyroid cancer. Jendokrinnaja hirurgija. 2014; 1: 47–52 [in Russian].

6. Rumjancev P.O. The role of targeted therapy with multikinase inhibitors in the treatment of radioiodine-differentiated thyroid cancer. Klinicheskaja i jeksperimental’naja tireodologija. 2015; 11(2): 25–32 [in Russian].

7. Semenov D.Ju., Boriskova M.E., Zarajskij M.I. i dr. Determination of BRAF mutation in the papillary microcarcinoma of the thyroid gland is an additional marker of risk stratification. Klinicheskaja i jeksperimental’naja tireodologija. 2014; 10(3): 35–39 [in Russian].

8. Smirnova V.A., Semkina G.V., Platonova N.M., Vanushko V. Je. Papillary microcarcinoma of the thyroid gland. Klinicheskaja i jeksperimental’naja tireodologija. 2015; 11(2): 11–24 [in Russian].

9. Farhutdinova L.M. Oxidative stress. Background. Vestnik Akademii nauk Respubliki Bashkortostan. 2015; 20(1(77)): 42–49 [in Russian].

10. Farhutdinova L.M. Regional features of the microelement status of the human body in the development of thyroid and somatic pathology. Diss. …d-ra med. Nauk. Cheljabinsk: ChGMA. 2007; 249 р. [in Russian].

11. Chernikov R.A., Valdina E.A., Vorob’ev S.L. i dr. Long-term results of surgical treatment for papillary thyroid cancer and comparative evaluation of treatment tactics. Klinicheskaja i jeksperimental’naja tireodologija. 2014; 10(1): 31–37 [in Russian].

12. Lee YS, Lim H, Chang H-S, et al. Papillary thyroid microcarcinomas are different from latent papillary thyroid carcinomas at autopsy. J. Korean Med Sci. 2014.29.5.676.

13. Lin J-D. Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer. Med. Oncol. 2009; 27(2):510-518. doi: 10.1007/s12032-009-9242-8.

14. Shaha A. Treatment of thyroid cancer based on risk groups. J. Surg. Oncol. 2006. 94; 8:683 — 691. PMID: 17131422

15. Takami H, Ito Y, Okamoto T, et al. Revisiting the guidelines issued by the japanese society of thyroid surgeons and japan association of endocrine surgeons: A gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma. World J. Surg. 2014; 38(8):2002-2010. doi: 10.1007/s00268-014-2498-y